Nanovibronix (NASDAQ:NAOV) Shares Down 4.5% – Should You Sell?

Posted by Tristan Rich on Jan 13th, 2026

Nanovibronix, Inc. (NASDAQ:NAOV – Get Free Report) traded down 4.5% during trading on Monday . The company traded as low as $4.01 and last traded at $4.1150. 32,840 shares traded hands during trading, an increase of 5% from the average session volume of 31,334 shares. The stock had previously closed at $4.31.

Analyst Upgrades and Downgrades

NAOV has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Nanovibronix from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Research Report on Nanovibronix

Nanovibronix Price Performance

The company has a market cap of $4.49 million, a price-to-earnings ratio of -0.10 and a beta of 2.05. The business’s 50-day simple moving average is $4.24 and its 200-day simple moving average is $6.15.

Nanovibronix (NASDAQ:NAOV – Get Free Report) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.91) EPS for the quarter. Nanovibronix had a negative net margin of 275.12% and a negative return on equity of 24.78%. The business had revenue of $0.72 million during the quarter.

About Nanovibronix

(Get Free Report)

Nanovibronix, Inc is a medical technology company that develops and markets noninvasive, wearable ultrasound devices for therapeutic applications. The company’s core focus lies in wound management and pain relief using its proprietary ultrasonic platform, which delivers low-intensity acoustic energy through lightweight, disposable transducers. Nanovibronix’s products are designed to accelerate tissue repair, reduce inflammation and minimize reliance on pharmaceuticals in both acute and chronic care settings.

The company’s flagship offerings include the Dermacare System for chronic wound therapy and the PainShield System for postoperative pain management.